A randomized study of single agent vs combination chemotherapy in FIGO stages IIB, III and IV ovarian adenocarcinoma.

[1]  C. Cohen,et al.  Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO Stages III and IV) as measured by surgical end-staging (second-look operation). , 1983, American journal of obstetrics and gynecology.

[2]  J. Blessing,et al.  A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma , 1983, Cancer.

[3]  P. Dombernowsky,et al.  High-dose medroxyprogesterone acetate (MPA) in advanced chemotherapy-resistant ovarian carcinoma: a phase II study. , 1982, Cancer treatment reports.

[4]  F. Costa,et al.  Advanced ovarian carcinoma: A prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa‐CAF) , 1981, Cancer.

[5]  P. Schwartz,et al.  Epithelial carcinoma of the ovary: current strategies. , 1981, Annals of internal medicine.

[6]  H. Hansen,et al.  Phase II clinical trial of VP-16-213 in ovarian cancer. , 1981, Cancer treatment reports.

[7]  L. Lagasse,et al.  Treatment of women with disseminated or recurrent advanced ovarian cancer with melphalan alone in combination with 5‐fluorouracil and dactinomycin or with the combination of cytoxan, 5‐fluorouracil and dactinomycin , 1980, Cancer.

[8]  T. Fleming,et al.  Different chemotherapeutic sensitivities and host factors affecting prognosis in advanced ovarian carcinoma versus minimal residual disease. , 1979, Cancer treatment reports.

[9]  J. Horton,et al.  Controlled prospective trial of combination chemotherapy with cyclophosphamide, adriamycin, and 5-fluorouracil for the treatment of advanced ovarian cancer: a preliminary report. , 1979, Cancer treatment reports.

[10]  S. Vogl,et al.  The CHAD and HAD regimens in advanced ovarian cancer: combination chemotherapy including cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II). , 1979, Cancer treatment reports.

[11]  R. Fisher,et al.  Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. , 1978, The New England journal of medicine.

[12]  Piver Ms,et al.  Single agent vs combination chemotherapy in the treatment of ovarian cancer. , 1977 .

[13]  H. Hansen,et al.  Phase II trial of amsacrine (m-AMSA) in advanced ovarian carcinoma. , 1982, European journal of cancer & clinical oncology.

[14]  N. Nissen,et al.  Acute non‐lymphocytic leukemia in patients with ovarian carcinoma following long‐term treatment with treosulfan (=dihydroxybusulfan) , 1980, Cancer.